Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus NEXAVAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus NEXAVAR.
BOSUTINIB MONOHYDRATE vs NEXAVAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
Multikinase inhibitor targeting Raf, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, Flt-3, and RET kinases, inhibiting tumor growth and angiogenesis.
400 mg orally once daily with food.
400 mg (two 200 mg tablets) orally twice daily approximately 12 hours apart on an empty stomach (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Terminal half-life 25-48 hours; supports twice-daily dosing with steady state achieved in 7-14 days.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Fecal (77% as unchanged drug and metabolites), renal (19% as metabolites, <1% as unchanged drug).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor